Osteoporosis is an osteolytic disease which features enhanced osteoclast formation and bone resorption. Identification of agents that can inhibit osteoclast formation and function is important for the treatment of osteoporosis. Dihydroartemisinin is a natural compound used to treat malaria but its role in osteoporosis in not known. Here, we found that dihydroartemisinin can suppresses RANKL-induced osteoclastogenesis and bone resorption in a dose dependent manner. Dihydroartemisin inhibited the expression of osteoclast marker genes such as cathepsin K, calcitonin receptor, and TRAcP. Furthermore, Dihydroartemisinin inhibited RANKL-induced NF-κB and NFAT activity. In addition, using an in vivo ovariectomized mouse model, we show that dihydroartemisinin is able to reverse the bone loss caused by ovariectomy. Together, this study shows that dihydroartemisinin attenuates bone loss in ovariectomized mice through inhibiting RANKL-induced osteoclast formation and function, indicating that dihydroartemisinin is a potential treatment option against osteolytic bone diseases.
INTRODUCTION
Bone is a continuously renewing tissue which is formed by mineralization of an organic matrix. Bone formation by osteoblasts and bone resorption by osteoclasts contributes to the balance of bone remodelling. An imbalance between osteoclast and osteoblast formation and function causes many osteopathic diseases, such as osteoporosis and Paget's disease [1, 2] .
Osteoporosis is a common age-related degenerative disease which often affects postmenopausal women due to oestrogen deficiency. According to the 2004 US surgeon General's report, it was estimated that women over 50 years old have a 50% risk of fragility fracture during the remainder of their lifetime, while men of same age have a 20% risk of fragility fracture throughout the remainder of their life time [3] . Fractures caused by osteoporosis are associated with significant morbidity and mortality, and place a large economic burden on society [4] .
The functional role of the osteoclast is to resorb bone through secreting acid and proteases to dissolve the organic and mineral components of bone. Receptor activator of nuclear factor kappa-B ligand (RANKL), also called osteoprotegerin ligand (OPGL), TNF-related activation-induced cytokine (TRANCE), and osteoclast differentiation factor (ODF), is a critical cytokine for the formation and activation of osteoclasts [5] [6] [7] . The interaction between RANKL and its receptor RANK activates several transcription factors, such as NF-κB, AKT, Activator Protein 1(AP-1), Mitogen Activated Protein kinase (MAPK) and Nuclear Factor of Activated T-cell cytoplasmic 1(NFATc1). Activation of these downstream factors triggers the expression of genes governing osteoclast differentiation and function, including TRACP, Cathepsin K, Matrix Metalloproteinase 9 (MMP-9), and calcitonin receptor (CTR) ultimately resulting in the production of mature multinucleated osteoclasts [8] [9] [10] . RANKL is now recognised as an attractive target for the treatment of osteoporosis, as inhibition of RANKL using antibodies, peptides and natural compounds could prevent osteoclast formation and function. This study aims to determine the effect of several natural compounds on inhibiting RANKL induced osteoclast formation and function.
Artemisinin is an effective drug for treating malaria. It belongs to the family of sesquiterpene lactones, which are produced by an Artemisia annua plant [11] . Dihydroartemisinin (DHA) is a water-soluble semi-synthetic derivative of artemisinin [12, 13] and it is commercially combined with piperaquine as an effective therapy for malaria [14] with few side effects [15] .
DHA has also been found to have the inhibitory effects on cancer cells mainly through modulating the NF-κB pathway [16] [17] [18] [19] . However, the effect of DHA on osteoclast formation and osteoporosis is not known.
In this study, we examine the role of DHA in osteoporosis in vivo using an ovariectomized (OVX) mouse model, and elucidate its cellular and molecular mechanism of action. We demonstrate that DHA has a protective effect in an oestrogen deficiency-induced osteoporosis mouse model. Furthermore, we found that DHA inhibits the formation and function of osteoclasts via inhibition of the NF-κB and NFAT pathways. As DHA is already used for treatment of malaria and has anti-tumour activity, our study further indicates that DHA could be beneficial for the treatment of osteolytic bone conditions, such as cancer or inflammation-induced osteolysis.
METHODS

Materials and Reagents
DHA was purchased from Chengdu Must Bio-Technology Co., Ltd (Chengdu, Sichuan Province, China), and dissolved in dimethyl sulfoxide (DMSO). Alpha modified Eagles Medium (α-MEM) and fetal bovine serum (FBS) were obtained from TRACE (Sydney, Australia). Anti-P-ERK and anti-IκBα antibodies were purchased from Santa Cruz Biotechnology (California, USA), anti-NFATc1 antibody was purchased from BD Bioscience (America) and V-ATPase-d2 was generated as previously described [20] . Mouse anti-β-Actin (catalog number: JLA20) was purchased from Developmental Studies Hybridoma Bank (DSHB) (Iowa, IA, USA). The luciferase assay system and MTS assay kit were purchased from Promega (Sydney, Australia). Recombinant GST-rRANKL protein was produced according to a previous paper [21] and recombinant macrophage colony stimulating factor (M-CSF) was used as previously described [22] .
In vitro osteoclastogenesis assay
Freshly isolated bone marrow macrophages (BMM) from C57BL/6 mice were cultured in T75 flasks in α-MEM containing M-CSF. When confluent, BMMs were seeded into 96 well plates at 1x10 6 cells per well with α-MEM and M-CSF overnight. The next day, BMMs were stimulated with 50 ng/ml RANKL and in the presence of DHA for every two days until osteoclasts formed. The plate was then fixed with 2.5% glutaraldehyde in phosphate-buffered saline (PBS) for 10 minutes, and stained for tartrate-resistant acidic phosphatase activity (TRAcP). TRAcP positive multinucleated cells with three or more nuclei were scored as osteoclast-like (OCL) cells.
In vitro osteoblast differentiation and mineralization
For osteoblastogenesis assays, osteoblast precursors from adult calvaria or long bones were obtained as outgrowth from collagenase-treated bone pieces as described previously [23] . The cells were plated into culture dishes at a cell density of 1×10 6 cells/ml in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% heat-inactivated FBS, 2mM L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin (complete DMEM). When confluent osteogenic media (complete DMEM, 10 nM dexamethasone, 10 mM β-glycerophosphate, and 50 µg/ml ascorbate) was added and cells cultured for 7 days (alkaline phosphatase assay) or 21 days (mineralisation). Alkaline phosphatase staining was performed using the Leukocyte alkaline phosphatase staining kit (Sigma, Castle Hill, Australia). Mineralisation was observed following fixation and staining with 1% alizarin red [24] . ImageJ software was used to measure the mineralized area [25] .
MTS assay for cell proliferation and viability
MTS assay was used to determine the effects of compounds on BMM cells using a commercially available MTS assay kit (Promega, Sydney, Australia). BMMs were seeded on 96-well plates at 6x10 3 cells per well and incubated overnight. Varying concentrations of DHA were then added to BMMs and the cells were incubated with the compounds for 48 hours. MTS/PMS mixture was then added to each well for two hours according to manufacturer's instructions. The absorbance of MTS was measured by spectrophotometric absorbance at 490 nm using an ELISA plate reader (BMG, Germany).
Hydroxyapatite resorption assay
BMMs were seeded on to six-well collagen-coated culture plates at a density of 1x10 5 cells per well. Cells were allowed to adhere overnight at 37°C and cells were then stimulated with 50ng/ml RANKL and M-CSF until osteoclasts began to form. The cells were gently harvested using cell dissociation solution, counted and equal numbers of multinucleated cells were seeded onto hydroxyapatite-coated plates (Corning, America). DHA was added to the cells after they were seeded onto the hydroxyapatite plate. After 48 hours, half of the wells were fixed and stained for TRAcP activity for osteoclast counting and the remainder of the wells were bleached and dried for hydroxyapatite resorption visualisation using a Nikon microscope and analysed using Image J software.
RNA extraction and analysis
Freshly isolated BMM cells from C57BL/6 mice were cultured in T75 flasks then seeded in six-well plates at a density of 1x10 5 Cells were then lysed and centrifuged for 20 minutes at 14000g at 4°C. Luciferase activity was then measured using the Promega luciferase kit and a BMG Polar Star Optima luminescence reader (BMG, Germany).
NF-κB and NFAT luciferase assay
Western blot assays
Freshly isolated BMM cells from C57BL/6mice were seeded into six-well plates, and stimulated with RANKL and M-CSF in the presence of DHA. After 5 days, osteoclasts had formed and cells were lysed with RIPA buffer for protein extraction. Protein was separated by SDS-PAGE electrophoresis, and then transferred to a nitrocellulose membrane. The membrane was blocked in a 5% skim milk for 1 hour then probed with specific antibodies, including P-ERK, ERK, IKBα, NFATc1, V-ATPase-d2, and β-actin antibodies. After washing three times with TBST, membranes were incubated with appropriate HRPconjugated secondary antibodies. Finally, the membrane was developed using Enhanced Chemiluminescence (ECL) reagents (Amersham) according to manufacturer's instructions and imaged using an Image quant LAS 4000 (GE Healthcare, Australia).
Ovariectomized (OVX) mouse model
The animal experiments were approved by the Institutional Animal Ethics Committee of Guangxi Medical University. Eighteen C57BL/6 mice aged 7 weeks old were randomly divided into three groups, which were sham group, OVX group and OVX+DHA (1mg/kg) group. Each group contained 6 mice. OVX group and OVX+DHA group were given an ovariectomy operation, while the sham group were given a sham operation as a control. After the procedure all mice had one week for postoperative recovery. Then the mice in OVX+DHA group were given intraperitoneal injection of DHA at 1mg/kg for every two days. The mice in the sham and OVX group were intraperitoneally injected with 4% DMSO as a control. After 6 weeks, all the mice were sacrificed. Their tibiae were collected and fixed in 10% neutral buffered formalin. Excess soft tissue was removed and the cleaned tibias were prepared for microCT analysis by wrapping in tissue soaked in phosphate buffered saline (PBS) and loading into a 2ml Eppendorf tube to maintain position, hydration, and to prevent movement artefacts. Tubes were then immobilised using foam inserts in the bed of a Skyscan 1176 microCT instrument (Bruker). Each tibia was then imaged with the following instrument settings: 50kV, 500μA, 0.5mm Al filter, 952ms exposure, pixel size 8.89 μm, 2 frame averaging, 0.4° rotation step through 180°. Images were then reconstructed using NRecon software (Bruker) with a constant threshold value. A volume of interest containing the proximal head of the tibia was generated and this volume was loaded into the analysis program CTAn (Bruker). A refined volume of interest was then generated 0.5mm below the growth plate and 1mm in height. The trabecular bone region of interest (ROI) within this volume was manually defined and bone parameters within this ROI were determined using a constant threshold for binarisation of the trabecular bone. Following microCT analysis bones were decalcified and embedded into paraffin blocks for sectioning and staining. Sequential 5μm thick sections were prepared and stained using haematoxylin and eosin, or for TRACP activity. Sections were scanned using Aperio Scanscope, and bone histomorphometric analyses were performed using BIOQUANT OSTEO software (Nashville, USA).
Statistical analysis
All values are presented as the mean ± standard deviation (SD) of the values obtained from three or more experiments. Statistical significance was determined by Student's t test. A P value of less than 0.05 was considered to be significant.
RESULTS
DHA inhibits RANKL induced osteoclastogenesis
In order to determine the effect of DHA on the formation of osteoclasts, osteoclastogenesis assays were performed. BMMs were seeded in 96 well plate at 6x10 3 per well. After overnight incubation, DHA was added to the plate every two days until osteoclasts were formed. The results showed that DHA inhibited RANKL induced osteoclastogenesis in a dose-dependent manner. DHA significantly inhibited osteoclast formation at doses greater than 0.5 µM ( Fig.1B. C) . To determine any cytotoxic effects of DHA on BMM, a cell survival assay was performed. Our results showed that concentrations of DHA that were effective at inhibiting osteoclastogenesis (0.5µM and 1µM) did not have any cytotoxic effects on BMM (Fig.1D) . Similar results were also found when BMM were treated with artemisinin; however, the effect of artemisinin was weaker than that of DHA. The minimum dose of artemisinin which significantly inhibited osteoclastogenesis was 1µM ( Supplementary   Fig. 1 ). We also assessed the effect of DHA on osteoblast formation and mineralization using in vitro osteoblastogenesis assays. We found no effect of DHA on osteoblast alkaline phosphatase staining, and no changes in mineralization in osteoblast cultures ( Supplementary   Fig. 2) . Thus, for the subsequent studies, DHA was chosen as a prototype to further examine its mechanism of action in osteoclastogenesis and therapeutic potential in vivo.
DHA suppresses RANKL induced osteoclast function
Hydroxyapatite-coated plates were used to test the effect of 48 hour treatment with DHA on mature osteoclast resorptive function. The percentage of resorbed area per osteoclast was reduced in the presence of DHA. The number of osteoclasts was also reduced by DHA but to a lesser degree relative to resorbing area (Fig.2) . These results suggested that DHA restrains the bone resorbing activity of osteoclasts.
DHA inhibits RANKL-induced gene expression
Real time PCR was used to assess the effect of DHA on RANKL-induced gene expression levels during osteoclastogenesis. The results showed that the expression of the osteoclast marker genes cathepsin K, calcitonin receptor and TRAcP were significantly and dosedependently inhibited by DHA at day 5 of culture. These results were consistent with osteoclast formation and activity assays (Fig.3) .
DHA suppresses RANKL-induced NF-κB activation and ERK phosphorylation
In order to further explore the mechanism of inhibition by DHA on osteoclast differentiation and activity, NF-κB luciferase reporter assay and IκBα degradation analysis was performed.
RAW264.7 cells stably transfected with an NF-κB luciferase reporter construct were pre-treated with different concentrations of DHA up to 5μM for 1 hour, then stimulated with 50ng/ml RANKL for another 6 hours. For Western blot assay, BMMs pre-treated for 1 hour with 1μM DHA were stimulated with RANKL for 0, 5, 10, 20, 30, 60 minutes. The results showed that DHA significantly inhibited NF-κB activation in a dose-dependent manner from the concentration of 0.5 µM (Fig. 4A) . The results of Western blot analysis showed that DHA at 1 µM significantly inhibited IκBα degradation relative to no treatment at 10 minutes poststimulation ( Fig. 4B. C) , and also strongly inhibited the RANKL-induced phosphorylation of ERK relative to total ERK (Fig. 4B. C) .
DHA suppresses RANKL-induced NFAT activation
To examine the effect of DHA on NFAT activation, NFAT luciferase reporter assay was performed. Similarly to the NF-κB luciferase reporter assay, RAW264.7 cells stably transfected with an NFAT luciferase reporter construct were first pre-treated with different concentrations of DHA up to 5 μM for 1 hour, followed by RANKL (50ng/ml) stimulation for another 24 hours. Cells were then harvested for luciferase activity measurement. The results showed that NFAT activation was significantly reduced by DHA at concentrations greater than 0.5 µM. DHA produced a greater than ten-fold reduction in NFAT activation at the concentrations of 2.5 and 5 µM (Fig. 5A ).
NFATc1 is a key transcription factor regulating the differentiation of osteoclasts, and autoamplifies its own transcription during osteoclastogenesis [26] . To assess NFATc1 protein levels, Western blot assay was performed with BMMs stimulated by RANKL (50ng/ml) for 0, 1, 3, and 5 days in the presence or absence of DHA. Protein levels of NFATc1 and V-ATPase-d2 were significantly reduced by DHA treatment consistent with the observed reduction in osteoclast formation ( Fig. 5B. C) . The maximum reduction of V-ATPase-d2 was at 5 days while the maximum reduction of NFATc1 was at 3 days ( Fig. 5B. C) .
DHA inhibits ovariectomy-induced bone loss
To determine the effect of DHA on ovariectomy-induced bone loss, mice were either sham operated, or ovariectomized (OVX) and were then treated with either DHA at a concentration of 1mg/kg every 2 days, or DMSO only control, by intraperitoneal injection for 6 weeks postsurgery. The tibias were then collected for micro-CT analysis. Our results showed that DHA treatment protected the mice from bone loss associated with OVX, as shown by increased BV/TV in treated mice relative to the OVX mice without treatment (Fig.6 ). Furthermore, trabecular separation (Tb.Sp) was significantly reduced in the OVX + DHA group when compared with OVX control group (Fig.6) . These results indicated that DHA protected against ovariectomy-induced bone loss.
To further confirm the effect of DHA on ovariectomy-induced bone loss, histomorphometric analysis was also performed. Consistent with the microCT results, there was an increase in BV/TV in the OVX + DHA group when compared with the OVX group (Fig.7 ). In addition, osteoclast surface/bone surface (Oc.S/BS) and osteoclast number/bone surface (N.Oc/Bs) were decreased in DHA treated OVX mice as compared with OVX group. Consistent with our in vitro results the osteoblast number/bone surface (N.Oc/Bs) was not significantly changed following DHA treatment versus the OVX group (Fig.7) . This result suggested that DHA protected against ovariectomy-induced bone loss through inhibiting osteoclast number and activity.
DISCUSSION
Artemisinin (Qinghaosu) is a natural compound extracted from Artemisia annua, which has been used to treat malaria in China for more than two thousand years. DHA is a semisynthetic derivative of artemisinin and is used in combination with piperaquine for the treatment of malaria patients, which is an effective remedy for malaria. Recently, DHA was also found to inhibit cancer cells, such as breast cancer cells [27, 28] and lung cancer cells [29, 30] . Furthermore, DHA was able to inhibit tumor angiogenesis [31] . DHA was found to exert these inhibitory effects on cancer cells through regulating the NF-κB pathway [16] [17] [18] [19] .
In this study, we have explored the effect of DHA on osteoclast formation and activity, and in an OVX-induced bone loss mouse model, as we found that DHA is more effective than artemisinin at inhibiting osteoclast formation.
Our results showed that DHA inhibited RANKL induced osteoclastogenesis at concentrations of 0.5 µM and higher without affecting the viability of BMM; however, mature osteoclast survival and function was affected at these doses, resulting in significant reductions in osteoclast activity. We also found that osteoblast formation and function was not affected by DHA treatment. These findings suggest that DHA might represent an efficient drug prototype for the treatment of osteoclast-mediated osteolysis.
In concordance with its inhibitory effect on osteoclastogenesis, DHA was found to suppress NF-κB in a luciferase reporter gene assay and significantly inhibit osteoclast marker gene expression. The RANKL induced NF-κB pathway is the major signal pathway activated during osteoclastogenesis [32] . The interaction between RANK and RANKL results in the rapid degradation of IκB by the proteasome and subsequent release of NF-κB, which then translocates from the cytoplasm to the nucleus. It then initiates transcription of osteoclast specific genes necessary for osteoclast differentiation and function [33] [34] [35] [36] . Our results have demonstrated an inhibitory effect of DHA on NF-κB activation through modulating IκBα protein levels, degradation, and downstream gene expression, indicating that DHA is inhibiting the NF-κB signaling pathway similar to its known mechanism of action in other cell types [16] [17] [18] [19] 37] .
DHA was also able to reduce NFAT activity in a luciferase reporter gene assay, and the expression of NFAT by Western blot assay. RANKL-induced NFATc1 is another important signaling pathway leading to osteoclast formation [38, 39] . The NFAT signalling cascade activates phospholipase C γ (PLCγ) and leads to the release of intracellular Ca 2+ , resulting in the activation of calcineurin and transcription and auto amplification of NFATc1 [40] . Our studies are the first to identify NFATc1 regulation by DHA, although it is interesting to note that the mechanism of DHA action in Plasmodium falciparum is to disrupt SERCA pumps resulting in Ca 2+ disturbances [41, 42] . Although it has been reported that artemisinin does not inhibit mammalian SERCA isoforms, DHA has not been assessed. The importance of Ca 2+ signaling in osteoclast NFAT activation may explain the sensitivity of osteoclasts to DHA. Similar inhibitory effects have been noted on osteoclast survival and differentiation using other SERCA inhibitors such as thapsigargin [43] .
NFAT signalling is also downstream of NF-κB, thus the suppression of NFATc1 by DHA could potentially result from the suppression of NF-κB signaling [44] . Thus, the inhibitory effect on NFATc1 by DHA could be due to indirect inhibition of NFAT through NF-κB. Our results showed that downstream targets of NFAT activation [20] , including V-ATPase-d2 that is important for osteoclast fusion [45, 46] , are inhibited by DHA suggesting that suppression of NFATc1 is an important component of the mechanism of DHA inhibition of RANKLinduced osteoclastogenesis.
In addition, our western blot results showed that DHA inhibits RANKL-induced ERK phosphorylation. The binding of RANKL to RANK also activates ERK, which is a mitogen activated protein kinase (MAPK) [47] that is downstream of tumor necrosis factor receptorassociated factor 6 (TRAF6) [48] . Inhibition of ERK phosphorylation has been observed in HUVEC cells treated with DHA [49] , and ERK is crucial for the survival of osteoclasts [50] .
Hence the observed reduction in ERK phosphorylation in the presence of DHA may account for the reduced survival that we observed in mature osteoclast cultures. Thus, the effect of DHA on osteoclasts is multifactorial via the inhibition of multiple signaling pathways including NF-κB, ERK and NFATc1 signaling pathways.
Based on the in vitro results, an OVX animal model was used for the evaluation of the function of DHA in osteoporosis. Our results showed that OVX mice were protected from bone loss by DHA treatment via inhibiting osteoclast formation and function, with no toxicity in mice. These preclinical experimental results are consistent with the in vitro results, and suggest that in addition to its anti-malaria [14] and anti-cancer effects [16] [17] [18] [19] , DHA has a new potential therapeutic effect against osteoporosis and other lytic bone diseases. 
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